Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells

Brain

Volumn 136, Issue 5, 2013, Pages 1462-1475

  Golebiewska, Anna ^a   Bougnaud, Sébastien ^a   Stieber, Daniel ^a   Brons, Nicolaas H C ^a   Vallar, Laurent ^a   Hertel, Frank ^b   Klink, Barbara ^c   Schröck, Evelin ^c   Bjerkvig, Rolf ^a,d   Niclou, Simone P ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

cancer stem cells; CD133; endothelial cells; glioblastoma; side population

Indexed keywords

ABC TRANSPORTER; BEVACIZUMAB; ENHANCED GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN BIOPSY; CANCER STEM CELL; ENDOTHELIUM CELL; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PLOIDY; PRIORITY JOURNAL; SIDE POPULATION CELL; TUMOR BIOPSY; TUMOR CELL; TUMOR XENOGRAFT;

EID: 84877300108     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt025     Document Type: Article

References (48)

1. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97: 12846-51.
2. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Exp Rev Mol Med 2011; 13: e17.
3. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) Glioma-Initiating cell population in human glioblastoma. Cancer Cell 2010; 18: 655-68.
4. Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland EC, et al. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 2012; 21: 11-24.
5. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
6. Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 2011; 10: 128.
7. Bernacki J, Dobrowolska A, Nierwinska K, Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008; 60: 600-22.
8. Bjerkvig R, Johansson M, Miletic H, Niclou SP. Cancer stem cells and angiogenesis. Semin Cancer Biol 2009; 19: 279-84.
9. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009; 4: 226-35.
10. Broadley KW, Hunn MK, Farrand KJ, Price KM, Grasso C, Miller RJ, et al. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 2011; 29: 452-61.
11. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010; 16: 2715-28.
12. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-27.
13. Challen GA, Little MH. A side order of stem cells: the SP phenotype. Stem Cells 2006; 24: 3-12.
14. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008; 7: 71-78.
15. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17: 362-75.
16. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, et al. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 2008; 27: 2091-6.
17. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10: 147-56.
18. Gazzin S, Strazielle N, Schmitt C, Fevre-Montange M, Ostrow JD, Tiribelli C, et al. Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J Comp Neurol 2008; 510: 497-507.
19. Golden PL, Pardridge WM. P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res 1999; 819: 143-6.
20. Golebiewska A, Brons NH, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011; 8: 136-47.
21. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-806.
22. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-33.
23. Huszthy PC, Daphu I, Niclou SP, Stieber D, Nigro JM, Sakariassen PO, et al. In vivo models of primary brain tumors: pitfalls and perspectives. Neurooncology 2012; 14: 979-93.
24. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011; 108: 3749-54.
25. Klink B, Schlingelhof B, Klink M, Stout-Weider K, Patt S, Schrock E. Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification. Anal Cell Pathol 2010; 33: 37-54.
26. Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F III. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011; 29: 11-9.
27. Mouthon MA, Fouchet P, Mathieu C, Sii-Felice K, Etienne O, Lages CS, et al. Neural stem cells from mouse forebrain are contained in a population distinct from the 'side population'. J Neurochem 2006; 99: 807-17.
28. Najbauer J, Huszthy PC, Barish ME, Garcia E, Metz MZ, Myers SM, et al. Cellular host responses to gliomas. PLoS One 2012; 7: e35150.
29. Niclou SP, Danzeisen C, Eikesdal HP, Wiig H, Brons NH, Poli AM, et al. A novel eGFP-expressing immunodeficient mouse model to study tumor-host interactions. FASEB J 2008; 22: 3120-8.
30. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, et al. Identification of A2B5 + CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62: 505-14, discussion 514-5.
31. Park DM, Rich JN. Biology of glioma cancer stem cells. Mol Cells 2009; 28: 7-12.
32. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 + and ABCG2-cancer cells are similarly tumorigenic. Cancer Res 2005; 65: 6207-19.
33. Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol 2008; 9: 1-22.
34. Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 2006; 103: 16466-71.
35. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36: 179-94.
36. Schulte A, Gunther HS, Martens T, Zapf S, Riethdorf S, Wulfing C, et al. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Clin Cancer Res 2012; 18: 1901-13.
37. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010; 133: 983-95.
38. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
39. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
40. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009; 4: 440-52.
41. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-9.
42. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22: 457-72.
43. Torok M, Huwyler J, Gutmann H, Fricker G, Drewe J. Modulation of transendothelial permeability and expression of ATP-binding cassette transporters in cultured brain capillary endothelial cells by astrocytic factors and cell-culture conditions. Exp Brain Res 2003; 153: 356-65.
44. Wang J, Miletic H, Sakariassen PO, Huszthy PC, Jacobsen H, Brekka N, et al. A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 2009; 9: 465.
45. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122: 761-8.
46. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008; 268: 1-9.
47. Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007; 67: 8216-22.
48. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-34.